Bellicum Pharma Comm (BLCM) |
|
3.77 -0.08 (-2.08%)
|
03-05 09:14 |
|
Open: |
4.03 |
Pre. Close: |
3.85 |
|
High:
|
4.45 |
Low:
|
3.51 |
|
Volume:
|
1,187,589 |
Market Cap:
|
23M |
|
|
|
|
Bellicum Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen; and BPX-603, a dual-switch GoCAR-T product candidate that is in Phase 1/2 clinical trials to treat solid tumors that express the human epidermal growth factor receptor 2 antigens. It has collaboration and license agreements with Adaptimmune Therapeutics plc, Agensys, Inc., BioVec Pharma, Inc., ARIAD Pharmaceuticals, Inc., and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Houston, Texas. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
4.455 - 4.491 |
4.491 - 4.516 |
|
Low:
|
3.449 - 3.482 |
3.482 - 3.503 |
|
Close:
|
3.725 - 3.778 |
3.778 - 3.814 |
|
Technical analysis |
as of: 2021-03-05 8:43:23 AM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 7.45  One year: 9.52 |
| Support: |
Support1: 3.51 Support2: 2.92 |
| Resistance: |
Resistance1: 6.38 Resistance2: 8.15 |
| Pivot: |
5.16 |
| Moving Average: |
MA(5): 4.11 MA(20): 5.06
MA(100): 4.19 MA(250): 5.61 |
| MACD: |
MACD(12,26): -0.11 Signal(9): 0.14 |
| Stochastic oscillator: |
%K(14,3): 2.76  %D(3): 3.49 |
| RSI: |
RSI(14): 38.41 |
| 52-week: |
High: 9.56 Low: 2.62 Change(%): -53.6 |
| Average Vol(K): |
3-Month: 93684 10-Days: 54918 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.BLCM has closed above bottom band by 16.4%. Bollinger Bands are 110.8% wider than normal. The large width of the bands suggest high volatility as compared to BLCM's normal range. The bands have been in this wide range for 13 bars. This is a sign that the current trend might continue. |
|
|
Headline News |
Thu, 04 Mar 2021
Bellicum Pharmaceuticals Inc (BLCM) Stock Loses -16.11% This Week; Should You Buy? - InvestorsObserver
Thu, 04 Mar 2021
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Wed, 03 Mar 2021
Bellicum Pharmaceuticals Inc. (BLCM) Plunges 7.67% on March 03 - Equities.com
Thu, 25 Feb 2021
Bellicum Pharmaceuticals Inc. (BLCM) Plunges 8.02% on February 25 - Equities.com
Fri, 19 Feb 2021
Is Bellicum Pharmaceuticals Inc (BLCM) Stock a Smart Value? - InvestorsObserver
Thu, 18 Feb 2021
Bellicum Pharmaceuticals Inc. (BLCM) Plunges 8.05% on February 18 - Equities.com
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
|
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Underperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Neutral |
Price to Earnings: |
Underperform |
| Return on Equity: |
Neutral |
Debt to Equity: |
Underperform |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
6 |
| Shares Float (M) |
5 |
|
% Held by Insiders
|
0.32 |
|
% Held by Institutions
|
23.90 |
|
Shares Short (K)
|
162 |
|
Shares Short P. Month (K)
|
293 |
Stock Financials |
|
EPS
|
-11.022 |
|
EPS Est This Year
|
-3.020 |
|
EPS Est Next Year
|
-2.950 |
|
Book Value (p.s.)
|
-9.490 |
|
Profit Margin
|
|
|
Operating Margin
|
-1057.41 |
|
Return on Assets (ttm)
|
-34.9 |
|
Return on Equity (ttm)
|
|
|
Qtrly Rev. Growth
|
|
|
Gross Profit (p.s.)
|
-9.070 |
|
Sales Per Share
|
0.841 |
|
EBITDA (p.s.)
|
-8.418 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-56 |
|
Levered Free Cash Flow (M)
|
-35 |
Stock Valuations |
|
PE Ratio
|
-0.34 |
|
PEG Ratio
|
|
|
Price to Book value
|
-0.40 |
|
Price to Sales
|
4.48 |
|
Price to Cash Flow
|
-0.41 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
